Advertisement

Topics

Immune Response in Patients Who Have Undergone Vaccine Therapy for Stage III or Stage IV Breast Cancer That Overexpresses HER2

2014-08-27 03:43:03 | BioPortfolio

Summary

RATIONALE: Studying the immune response to a vaccine made from HER2/neu protein may help doctors plan better treatment for patients with breast cancer that overexpresses HER2.

PURPOSE: This clinical trial is studying the immune response in patients who have undergone vaccine therapy for stage III or stage IV breast cancer that overexpresses HER2.

Description

OBJECTIVES:

Primary

- Determine whether immunologic memory to the HER-2/neu (HER2) intracellular domain (ICD) protein has been generated by active immunization with a HER2 ICD plasmid-based vaccine by assessing the delayed-type hypersensitivity response to HER2 ICD peptides 6 months after vaccination in patients with HER2-overexpressing stage III or IV breast cancer.

Secondary

- Characterize the memory T-cell population and quantitate memory precursor frequency at 3, 6, and 12 months after active immunization using intracellular cytokine staining.

OUTLINE: This is an open-label study.

Patients receive HER2 intracellular domain (ICD) protein mixture intradermally and sterile water injected intradermally (as a negative control) at 6 months post-vaccination with pNGVL3-hICD vaccine. Vital signs and injection site will be monitored prior to skin test and at 60 minutes post-test. Patients return 48-72 hours after skin test for delayed-type hypersensitivity (DTH) measurements. The injection site is biopsied and examined by immunohistochemistry for infiltrating T-cell and antigen-presenting cell populations.

Blood is drawn at 3, 6, and 12 months post-vaccination for assessment of immune memory response. Blood draws are coordinated with parent study. Blood samples are examined by flow cytometry for the presence of memory markers including L-selectin, CD45 isoforms, cytokines, and CCR7.

PROJECTED ACCRUAL: A total of 56 patients will be accrued for this study.

Study Design

Masking: Open Label, Primary Purpose: Diagnostic

Conditions

Breast Cancer

Intervention

HER-2/neu intracellular domain protein, flow cytometry, immunohistochemistry staining method, immunological diagnostic method, laboratory biomarker analysis, biopsy

Location

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Seattle
Washington
United States
98109-1024

Status

Recruiting

Source

National Cancer Institute (NCI)

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:43:03-0400

Clinical Trials [1606 Associated Clinical Trials listed on BioPortfolio]

Lenalidomide With or Without Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

RATIONALE: Lenalidomide and dexamethasone may stop the growth of multiple myeloma by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well lenalidomide works...

Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma

RATIONALE: Biological therapies may stimulate the immune system in different ways and stop cancer cells from growing. PURPOSE: This phase I trial is studying the side effects and best dos...

Evaluation of Patients Who Have Skin Diseases

RATIONALE: Evaluating patients who have skin diseases may help doctors plan more effective treatment and follow-up for skin diseases and systemic diseases that show up in the skin. PURPOS...

Study of Proteins in Head and Neck Cancer Cells

RATIONALE: Studying proteins in head and neck cancer cells in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. P...

Multidrug Resistance Proteins in Patients Enrolled in Clinical Trials Outside of the National Cancer Institute Center for Cancer Research

RATIONALE: Studying samples of tumor tissue or blood from patients with cancer in the laboratory may help doctors learn more about cancer and the development of multidrug resistance in pat...

PubMed Articles [25218 Associated PubMed Articles listed on BioPortfolio]

A standardized flow cytometry procedure for the monitoring of regulatory T cells in clinical trials.

Quantification of regulatory T cells is crucial in immunomonitoring in clinical trials as this cell population has been shown to be involved in a wide range of diseases, including cancers, autoimmune ...

Assessment of bacterial membrane fluidity by flow cytometry.

It can be interesting to evaluate the cytoplasmic membrane fluidity of bacteria in order to understand the impacts of stresses during processing. Traditionally, membrane fluidity was assessed by fluor...

Automated and simplified identification of normal and abnormal plasma cells in multiple myeloma by flow cytometry.

Multiple myeloma (MM) is an incurable disease characterized by clonal plasma cell (PC) proliferation within the bone marrow (BM). Next-generation flow cytometry has become the reference tool to follow...

High-throughput flow cytometry for drug discovery: principles, applications, and case studies.

Flow cytometry is a technology providing multiparametric analysis of single cells or other suspension particles. High-throughput (HT) flow cytometry has become an attractive screening platform for dru...

Flow cytometry in microbiology.

Flow cytometry is a method that allows simultaneous measurement and analysis of physical and chemical characteristics of cells or other biological particles during their passage through the laser beam...

Medical and Biotech [MESH] Definitions

A technique encompassing morphometry, densitometry, neural networks, and expert systems that has numerous clinical and research applications and is particularly useful in anatomic pathology for the study of malignant lesions. The most common current application of image cytometry is for DNA analysis, followed by quantitation of immunohistochemical staining.

A large class of structurally-related proteins that contain one or more LIM zinc finger domains. Many of the proteins in this class are involved in intracellular signaling processes and mediate their effects via LIM domain protein-protein interactions. The name LIM is derived from the first three proteins in which the motif was found: LIN-11, Isl1 and Mec-3.

A family of mammalian membrane glycoproteins characterized by extracellular IMMUNOGLOBULIN DOMAINS. Some members also have an intracellular B30.2-SPRY DOMAIN or SPRY DOMAIN. The butyrophilin protein (BTN) is expressed by MAMMARY GLAND EPITHELIUM during LACTATION; whereas other members are widely expressed in other tissues, including skeletal muscle, intestine, ERYTHROID CELLS (ERMAP protein); and nerve tissue (MYELIN-OLIGODENDROCYTE GLYCOPROTEIN).

Intracellular signaling adaptor proteins that bind to the cytoplasmic death domain region found on DEATH DOMAIN RECEPTORS. Many of the proteins in this class take part in intracellular signaling from TUMOR NECROSIS FACTOR RECEPTORS.

A subset of ubiquitin protein ligases that are formed by the association of a SKP DOMAIN PROTEIN, a CULLIN DOMAIN PROTEIN and a F-BOX DOMAIN PROTEIN.

More From BioPortfolio on "Immune Response in Patients Who Have Undergone Vaccine Therapy for Stage III or Stage IV Breast Cancer That Overexpresses HER2"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...


Searches Linking to this Trial